How Clovis’ Rociletinib And AstraZeneca’s AZD9291 Development Programs Stack Up
Executive Summary
Clovis and AstraZeneca have kept pace regarding submissions of breakthrough EGFR inhibitors rociletinib and AZD9291, but clinical trial programs suggests the big pharma is far ahead in overall development.